Filtered By:
Condition: Alzheimer's
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 255 results found since Jan 2013.
Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development
Cell Mol Neurobiol. 2023 Sep 19. doi: 10.1007/s10571-023-01408-7. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is the primary cause of dementia and is characterized by the death of brain cells due to the accumulation of insoluble amyloid plaques, hyperphosphorylation of tau protein, and the formation of neurofibrillary tangles within the cells. AD is also associated with other pathologies such as neuroinflammation, dysfunction of synaptic connections and circuits, disorders in mitochondrial function and energy production, epigenetic changes, and abnormalities in the vascular system. Despite extensive research con...
Source: Cellular and Molecular Neurobiology - September 19, 2023 Category: Cytology Authors: Bhavarth P Dave Yesha B Shah Kunal G Maheshwari Kaif A Mansuri Bhadrawati S Prajapati Humzah I Postwala Mehul R Chorawala Source Type: research
Recombinant Antibody Fragments for Neurological Disorders: An Update
Curr Neuropharmacol. 2023 Aug 30. doi: 10.2174/1570159X21666230830142554. Online ahead of print.ABSTRACTRecombinant antibody fragments are promising alternatives to full-length immunoglobulins, creating big opportunities for the pharmaceutical industry. Nowadays, antibody fragments such as antigen-binding fragments (Fab), single-chain fragment variable (scFv), single-domain antibodies (sdAbs), and bispecific antibodies (bsAbs) are being evaluated as diagnostics or therapeutics in pre-clinical models and in clinical trials. Immunotherapy approaches, including passive transfer of protective antibodies, have shown therapeutic...
Source: Current Neuropharmacology - August 30, 2023 Category: Drugs & Pharmacology Authors: Karen Manoutcharian Goar Gevorkian Source Type: research
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin
Curr Alzheimer Res. 2023 Aug 25. doi: 10.2174/1567205020666230825124922. Online ahead of print.ABSTRACTAlzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clinic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer's disease Psychosis (ADP). However, pimavanserine, an atypical antipsychotic, has been approved by the FDA for Parkinson's psychosis. It is predicted that pimavanserin, a new antipsychotic, will fill an important gap in t...
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Faruk Kurhan Mustafa Ak ın Source Type: research
Passive Alzheimer's immunotherapy: A promising or uncertain option?
Ageing Res Rev. 2023 Jul 4:101996. doi: 10.1016/j.arr.2023.101996. Online ahead of print.ABSTRACTThe US Food and Drug Administration (FDA)'s recent accelerated approval of two anti-amyloid antibodies for treatment of Alzheimer's disease (AD), aducanumab and lecanemab, has caused substantial debate. To inform this debate, we reviewed the literature on randomized clinical trials conducted with eight such antibodies focusing on clinical efficacy, cerebral amyloid removal, amyloid-related imaging abnormalities (ARIAs) and cerebral volumes to the extent such measurements have been reported. Two antibodies, donanemab and lecanem...
Source: Ageing Research Reviews - July 6, 2023 Category: Genetics & Stem Cells Authors: Poul F H øilund-Carlsen Mona-Elisabeth Revheim Tommaso Costa Abass Alavi Kasper P Kepp Stefano L Sensi George Perry Nikolaos K Robakis Jorge R Barrio Bryce Vissel Source Type: research
Physician Perspectives on FDA's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease
Clin Pharmacol Ther. 2023 May 23. doi: 10.1002/cpt.2954. Online ahead of print.ABSTRACTIn June 2021, the Food and Drug Administration (FDA) granted accelerated approval to aducanumab, a monoclonal antibody indicated for the treatment of Alzheimer's Disease. The accelerated approval decision was controversial due to concerns about the use of an unvalidated surrogate measure, beta-amyloid, as the basis for approval and a lack of clinical outcome benefit. Between October 2021 and September 2022, we conducted a survey of a nationally representative group of internists, medical oncologists, and cardiologists to understand persp...
Source: Clinical Pharmacology and Therapeutics - May 23, 2023 Category: Drugs & Pharmacology Authors: Sanket S Dhruva Aaron S Kesselheim Steven Woloshin Robin Z Ji Zhigang Lu Jonathan J Darrow Rita F Redberg Source Type: research
